- Home
- HOFT vs SLS Comparison
HOFT vs SLS Comparison
Compare HOFT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- SLS
- Stock Information
- Founded
- HOFT 1924
- SLS 2012
- Country
- HOFT United States
- SLS United States
- Employees
- HOFT N/A
- SLS N/A
- Industry
- HOFT Home Furnishings
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- HOFT Consumer Discretionary
- SLS Health Care
- Exchange
- HOFT Nasdaq
- SLS Nasdaq
- Market Cap
- HOFT 98.1M
- SLS 89.6M
- IPO Year
- HOFT 1999
- SLS N/A
- Fundamental
- Price
- HOFT $8.69
- SLS $1.31
- Analyst Decision
- HOFT
- SLS
- Analyst Count
- HOFT 0
- SLS 0
- Target Price
- HOFT N/A
- SLS N/A
- AVG Volume (30 Days)
- HOFT 107.8K
- SLS 1.1M
- Earning Date
- HOFT 04-17-2025
- SLS 05-13-2025
- Dividend Yield
- HOFT 10.59%
- SLS N/A
- EPS Growth
- HOFT N/A
- SLS N/A
- EPS
- HOFT N/A
- SLS N/A
- Revenue
- HOFT $397,465,000.00
- SLS N/A
- Revenue This Year
- HOFT $12.50
- SLS N/A
- Revenue Next Year
- HOFT $7.72
- SLS N/A
- P/E Ratio
- HOFT N/A
- SLS N/A
- Revenue Growth
- HOFT N/A
- SLS N/A
- 52 Week Low
- HOFT $7.34
- SLS $0.77
- 52 Week High
- HOFT $19.79
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- HOFT 38.06
- SLS 66.32
- Support Level
- HOFT $7.77
- SLS $0.95
- Resistance Level
- HOFT $8.61
- SLS $1.36
- Average True Range (ATR)
- HOFT 0.79
- SLS 0.08
- MACD
- HOFT -0.04
- SLS 0.03
- Stochastic Oscillator
- HOFT 42.45
- SLS 87.80
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp designs, imports, manufactures and market residential household furniture, hospitality and contract furniture, lighting, accessories, and home décor for sale to wholesale and retail merchandisers located principally in North America.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.